In a report released today, Marie Thibault from BTIG maintained a Hold rating on Embecta Corporation (EMBC – Research Report). The company’s shares opened today at $16.02.
According to TipRanks, Thibault is an analyst with an average return of -5.3% and a 27.57% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Boston Scientific, Masimo, and Beyond Air.
Currently, the analyst consensus on Embecta Corporation is a Moderate Sell with an average price target of $16.00.
See the top stocks recommended by analysts >>
EMBC market cap is currently $953M and has a P/E ratio of 20.25.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EMBC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Embecta Corporation (EMBC) Company Description:
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
Read More on EMBC:
- Embecta Corp. Reports Fiscal 2023 Fourth Quarter and Full Year Financial Results and Provides Initial Fiscal 2024 Financial Guidance
- embecta Announces Quarterly Cash Dividend
- Embecta Corporation (EMBC) Q4 Earnings Cheat Sheet
- embecta to Recognize National Diabetes Awareness Month by Ringing Nasdaq Opening Bell
- embecta to Report Fiscal Fourth Quarter and Full Year 2023 Financial Results
